# A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS

> **NCT06249867** · PHASE2 · RECRUITING · sponsor: **Oliver Blanchard** · enrollment: 30 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Darifenacin 7.5 MG Extended Release Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06249867
- **Lead sponsor:** Oliver Blanchard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2027-08
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06249867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06249867, "A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06249867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*